bioAffinity Technologies, Inc.
BIAF
$1.62
$0.053.19%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -27.66% | 4.99% | 78.40% | 269.68% | 2,814.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -27.66% | 4.99% | 78.40% | 269.68% | 2,814.72% |
| Cost of Revenue | -19.67% | 14.11% | 74.34% | 243.70% | 7,887.14% |
| Gross Profit | -42.47% | -11.60% | 86.67% | 326.79% | 1,237.79% |
| SG&A Expenses | 6.06% | 11.86% | 30.42% | 46.43% | 60.31% |
| Depreciation & Amortization | -10.99% | 12.94% | 61.71% | 142.53% | 455.27% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.15% | 11.00% | 38.70% | 74.34% | 133.86% |
| Operating Income | -24.35% | -16.07% | -15.25% | -12.29% | -15.09% |
| Income Before Tax | -74.31% | -33.55% | -16.38% | -14.05% | -16.79% |
| Income Tax Expenses | 192.14% | 194.16% | 29.46% | -44.29% | -25.13% |
| Earnings from Continuing Operations | -74.51% | -33.80% | -16.40% | -13.89% | -16.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.51% | -33.80% | -16.40% | -13.89% | -16.68% |
| EBIT | -24.35% | -16.07% | -15.25% | -12.29% | -15.09% |
| EBITDA | -27.09% | -16.26% | -11.71% | -8.08% | -8.43% |
| EPS Basic | 13.47% | 22.86% | 22.68% | 17.52% | 5.85% |
| Normalized Basic EPS | 13.56% | 22.96% | 22.70% | 17.41% | 5.76% |
| EPS Diluted | 13.47% | 22.86% | 22.68% | 17.52% | 5.85% |
| Normalized Diluted EPS | 13.56% | 22.96% | 22.70% | 17.41% | 5.76% |
| Average Basic Shares Outstanding | 102.34% | 71.48% | 50.32% | 38.56% | 26.32% |
| Average Diluted Shares Outstanding | 102.34% | 71.48% | 50.32% | 38.56% | 26.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |